Hutchinson-Gilford Progeria Syndrome Clinical Trial
Official title:
Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest infringements of the disease, to prolong the life of the children, and in a more general way, aim at improving their living conditions.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03871972 -
Umbilical Cord Blood Transfusion in Progeria Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT04512963 -
Phase I Study of Progerinin in Healthy Volunteers
|
Phase 1 |